Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Biostar Pharmaceuticals Co PS Ratio?
Beijing Biostar Pharmaceuticals CoHKSE:02563 -0.15%9 PS Ratio is 33.75 as of Aug. 15, 2026, which is 9% below its 10-year median of 37.06. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review. Among 931 Biotechnology companies, Beijing Biostar Pharmaceuticals Co ranks worse than 74.76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beijing Biostar Pharmaceuticals Co's share price is HK$3.375.
Beijing Biostar Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.10. Hence, Beijing Biostar Pharmaceuticals Co's PS Ratio for today is 33.75.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Beijing Biostar Pharmaceuticals Co PS Ratio Related Terms
Beijing Biostar Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co PS Ratio Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
86.76
47.52
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
HKSE:02563 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's PS Ratio falls into.
Beijing Biostar Pharmaceuticals Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Beijing Biostar Pharmaceuticals Co's Share Price of today is HK$3.375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Biostar Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a PS Ratio of 33.75 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. This is near median its historical median of 37.06. Over the past decade, Beijing Biostar Pharmaceuticals Co's PS Ratio has ranged from 13.42 to 159.75. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #696 out of 931 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Beijing Biostar Pharmaceuticals Co's PS Ratio too high?
Beijing Biostar Pharmaceuticals Co's current PS Ratio of 33.75 is near median its 10-year median of 37.06. Over the past 10 years, this metric has ranged from a low of 13.42 to a high of 159.75. The Biotechnology industry median PS Ratio is 9.55. Beijing Biostar Pharmaceuticals Co's value of 33.75 is 253.4% above this industry median. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #696 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #696 out of 931 companies for PS Ratio. This places Beijing Biostar Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 9.55. Beijing Biostar Pharmaceuticals Co's value of 33.75 is 253.4% above this benchmark. Historically, Beijing Biostar Pharmaceuticals Co's own PS Ratio has ranged from 13.42 to 159.75 over the past decade. While the company's 10-year median is 37.06 vs. the industry median of 9.55, Beijing Biostar Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Biostar Pharmaceuticals Co's current PS Ratio of 33.75 is 253.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Biostar Pharmaceuticals Co's current PS Ratio is 33.75, which is near median its own 10-year median of 37.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current PS Ratio of 33.75. The current PS Ratio is 33.75, which is near median its 10-year median of 37.06 and 253.4% above the Biotechnology industry median of 9.55. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current PS Ratio is 33.75 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
